Netupitant and Palonosetron
Brand Names: Akynzeo
Methodology & AI Transparency ⓘ
Netupitant and Palonosetron Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: 1 Indications and usage akynzeo: capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy.
- 2 Real-world patient consensus: 81% patient "Worth It" rating across 6 anonymous logs for Netupitant and Palonosetron (RxNorm 1552343).
- 3 Typical cash cost range: Dispensing cost comparison spans $109.75 mail/discount cash up to $268.89 uninsured retail (federal NADAC $2.5000).
- 4 Top reported side effects / signs: Key post-marketing and trial adverse reactions (Netupitant and Palonosetron): nausea (10.6%), headache (9.2%), fatigue (8.3%).
Ask our AI Specialists anything about Netupitant and Palonosetron
Netupitant and Palonosetron Mechanism, CYP450 Pathways & DailyMed Monograph
1 Indications and usage akynzeo: capsules is indicated in combination with dexamethasone in adults for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of cancer chemotherapy, including, but not limited to, highly emetogenic chemotherapy. AKYNZEO capsules is a combination of palonosetron and netupitant: palonosetron prevents nausea and vomiting during the acute phase and netupitant prevents nausea and vomiting during both the acute and delayed phase after cancer chemotherapy.
12.1 Mechanism of Action Netupitant is a selective antagonist of human substance P/neurokinin 1 (NK-1) receptors. Palonosetron is a 5-HT 3 receptor antagonist with a strong binding affinity for this receptor and little or no affinity for other receptors. Cancer chemotherapy may be associated with a high incidence of nausea and vomiting, particularly when certain agents, such as cisplatin, are used. 5-HT 3 receptors are located on the nerve terminals of the vagus in the periphery and centrally in the chemoreceptor trigger zone of the area postrema.
Systemic exposure to Netupitant and Palonosetron reflects F ≈ 52%–64% systemic availability after standard oral Netupitant and Palonosetron administration absorption kinetics and netupitant and palonosetron undergoes cyp3a4-mediated hepatic metabolism prior to excretion, sustaining receptor engagement across a Terminal t½ estimated at 10–17 hrs depending on renal/hepatic reserve (Netupitant and Palonosetron) half-life window (time to peak concentration spans 1 to 3 hrs under netupitant and palonosetron maintenance response profile).
Dosing protocols (300 mg/1 / .5 mg/1 Capsule or Organ-function-adjusted Netupitant and Palonosetron maintenance interval) balance efficacy (81.00% patient satisfaction across 6 logs) against nausea (10.6% of reports), headache (9.2% of reports), fatigue (8.3% of reports), with strict avoidance in known hypersensitivity to netupitant and palonosetron or structurally related substance p/neurokinin-1 receptor antagonist compounds; concomitant contra-labeled cyp/transporter therapies during active netupitant and palonosetron administration.
Potent CYP3A4 modulators alter hepatic clearance of Netupitant and Palonosetron, shifting steady-state plasma concentrations.
Avoid overlapping substance p/neurokinin-1 receptor antagonist prescriptions alongside Netupitant and Palonosetron to prevent cumulative receptor toxicity.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- Known hypersensitivity to Netupitant and Palonosetron or structurally related substance p/neurokinin-1 receptor antagonist compounds
- Concomitant contra-labeled CYP/transporter therapies during active Netupitant and Palonosetron administration
Logged Side-Effect Incidence (6 Reports)
Netupitant and Palonosetron Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Netupitant and Palonosetron)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Pooled Analysis of Studies Evaluating Fosnetupitant and Risk Factors for: What a 980-Participant Study Found This analysis revealed that fosnetupitant could have long-acting antiemetic potency (> 120 h) and indicated the importance of antiemetic therapy at 0-120 h for CINV up to 168 h after chemotherapy. Advances in therapy • 2023-11-15 • Phase III Randomized Trial | N = 980 | 87/100 | PMID 37715851 ↗ |
| Can This Approach Help? Inside the Latest Research on Reduced/No Dexamethasone With Netupitant/Palonosetron and Olanzapine for NEPA plus OLZ with reduced (6 mg day 1 only) or no DEX is noninferior to standard 4-day DEX for chemotherapy-induced nausea and vomiting prevention in HEC, supporting steroid-sparing strategies particularly relevant in the... Journal of clinical oncology : official journal of the American Society of Clinical Oncology • 2026-09-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 42241642 ↗ |
| Can This Approach Help? Inside the Latest Research on Dexamethasone-sparing regimens with NEPA (netupitant/palonosetron) for the Among the 228 patients in the parent study, 107 were > 65 years. Journal of geriatric oncology • 2023-07-15 • Phase III Randomized Trial | Multi-cohort | 82/100 | PMID 37290207 ↗ |
Netupitant and Palonosetron Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $2.5000/unit (~$75.00/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $268.89 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 6 Anonymous DotMD Community Micro-Logs | $109.75 / mo | View logs ↓ |
Netupitant and Palonosetron Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Netupitant and Palonosetron RxNorm Concept ID | 1552343 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $2.5000 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $268.89 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $109.75 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 81.00% Worth It (6 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Netupitant and Palonosetron Patient Community, Cohort Filters & Dosage Logs
Deterministic Netupitant and Palonosetron reference combining NIH RxNorm (1552343), Medicaid NADAC ($2.5000/unit), and anonymous cohort outcomes (81% Worth It).
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Netupitant and Palonosetron community threads and patient logs by age, biological sex, dosage, and treatment duration.